卫信康(603676.SH)：利多卡因丁卡因乳膏获得药物临床试验批准通知书

Core Viewpoint - Weitengkang (603676.SH) announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Lidocaine and Bupivacaine Cream [1] Group 1 - The approved product, Lidocaine and Bupivacaine Cream, was developed by Zars Company and was approved by the FDA in the United States on June 29, 2006, under the brand name Pliaglis [1] - The cream contains 70mg of Lidocaine and 70mg of Bupivacaine per gram [1]